A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway

Hepatology Research

Volumn 39, Issue 5, 2009, Pages 479-489

  Kogure, Takayuki ^a   Ueno, Yoshiyuki ^a   Kimura, Osamu ^a   Kondo, Yasuteru ^a   Inoue, Jun ^a   Fukushima, Koji ^a   Iwasaki, Takao ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Hepatocellular carcinoma; Metastasis

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; FARNESOL; GERANYLGERANIOL; MEVALONIC ACID; MINODRONIC ACID; SCATTER FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER INHIBITION; CELL DIVISION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION PROCESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

EID: 65449185439     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00484.x     Document Type: Article

References (44)

1. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
2. Kato Y, Nakata K, Omagari K et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994; 15: 2234-8.
3. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-61.
4. Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl 2006; 12: 1028-36.
5. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 15: 435-42.
6. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 15: 1890-6.
7. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53: 296-304.
8. Itoh Y, Ohkubo K, Iuchi H, Michitaka K, Horiike N, Onji M. Chronological changes of causes of death and distant metastasis in hepatocellular carcinoma. Oncol Rep 2002; 9: 331-5.
9. Fukutomi M, Yokota M, Chuman H et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001; 13: 1083-8.
10. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4: 711-19.
11. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 15: 2602-8.
12. Yonou H, Ochiai A, Ashimine S et al. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Prostate 2007; 17: 999-1009.
13. Sebbah-Louriki M, Colombo BM, el Manouni D et al. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res 2002; 22: 3925-31.
14. Takahashi R, Shimazaki C, Inaba T et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001; 25: 77-83.
15. Segawa H, Kimura S, Kuroda J et al. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk Res 2005; 29: 451-7.
16. Yuasa T, Nogawa M, Kimura S et al. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res 2005; 15: 853-9.
17. Koshimune R, Aoe M, Toyooka S et al. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer 2007; 7: 8.
18. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131-40.
19. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 1: 5294-7.
20. Oura S, Hirai I, Yoshimasu T, Kokawa Y, Sasaki R. Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer. Breast Cancer 2003; 10: 28-32.
21. Kohno N, Kokufu I. Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy. Breast Cancer 2003; 10: 33-7.
22. Nakajima H, Magae J, Tsuruga M et al. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett 2007; 8: 89-96.
23. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59: 193-202.
24. Dimitroulakos J, Ye LY, Benzaquen M et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications. Clin Cancer Res 2001; 7: 158-67.
25. Matar P, Rozados VR, Roggero EA, Scharovsky OG. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 1998; 13: 387-93.
26. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5: 2223-9.
27. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643-58.
28. Wada A, Fukui K, Sawai Y et al. Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol 2006; 44: 142-50.
29. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 2003; 10: 2655-64.
30. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane]localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002; 6: 1479-86.
31. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 2003; 15: 719-27.
32. Kubo T, Shimose S, Matsuo T et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 2006; 24: 1138-44.
33. Sherwood DR. Cell invasion through basement membranes: An anchor of understanding. Trends Cell Biol 2006; 16: 250-6.
34. Gupta GP, Massague J. Cancer metastasis: Building a framework. Cell 2006; 17: 679-95.
35. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-92.
36. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signal coupling to various transcription factors depends on triggering of Met receptor and protein kinase transducers in human hepatoma cells HepG2. Exp Cell Res 2000; 10: 272-81.
37. McCawley LJ, Li S, Wattenberg EV, Hudson LG. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999; 12: 4347-53.
38. Toyras A, Ollikainen J, Taskinen M, Monkkonen J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci 2003; 19: 223-30.
39. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 1: 2708-14.
40. Shimamura T, Amizuka N, Li M et al. Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res 2005; 26: 159-72.
41. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006; 12: 6305s-6308s.
42. Loberg RD, Gayed BA, Olson KB, Pienta KJ. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005; 15: 439-46.
43. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 18: 679-87.
44. Sato K, Yuasa T, Nogawa M et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006; 20: 1354-61.